This archive contains all documents published by cep over the last few years:
cepAdhoc: Incisive comment on current EU policy issues.
cepPolicyBrief: Concise 4-page reviews of EU proposals (Regulations, Directives, Green Papers, White Papers, Communications) – including a brief summary and economic and legal assessments.
cepInput: Impulse to current discussions of EU policies.
cepStudy: Comprehensive examination of EU policy proposals affecting the economy.
The EU Commission has submitted a "strategic approach" aimed at reducing pharmaceutical residues and their impact on the environment. The cep has analyzed and evaluated the Commission's communication on this issue.
On the basis of the Transparency Regulation, the CJEU has for the first time decided on third party access to documents submitted to the European Medicines Agency (EMA) by pharmaceutical companies. A cepInput explains the background and relevance of the CJEU proceedings and deals with the three main grounds for the decision in the "PTC Therapeutics" judgement.
In order to avoid impending shortages of medical devices as of May 2020 and with the aim to guarantee patient safety, the Council proposed an extension to the deadline for certain medical devices on 25 November 2019. The cep has assessed this in an Adhoc.
A further cepAdhoc assesses the main tasks which future EU Commission President Ursula von der Leyen will be entrusting to the future Commission Vice-President Jourová and Justice Commissioner Reynards, in the areas of rule of law, fundamental rights, consumer protection and European Parliament elections.
A cepAdhoc assesses the core health policy tasks which von der Leyen will be entrusting to the assigned Commissioners. Vice-President Schinas, in Public Health, and Executive Vice-President Timmermans, in Food Safety and Animal and Plant Protection, will work together with Commissioner Kyriakides.
A voluntary exchange format for electronic health records should facilitate cross-border healthcare in the EU. The EU Commission has drawn up a recommendation to this end.
In view of increasing EU-wide violations, the EU-Commission wants to strengthen the enforcement of, and thus improve compliance with, EU consumer protection law. In the context of its “New Deal for Consumers”, it has submitted a corresponding Directive.
By way of an exemption from protection certificates, the EU wants to permit the manufacture of generics and so-called biosimilars for export, even where the original medicine is still protected by a certificate in the EU. Using this exemption, it wants to remedy competitive disadvantages for EU manufacturers and strengthen its generics and biosimilars industry.